<DOC>
	<DOCNO>NCT01685255</DOCNO>
	<brief_summary>This open-label , randomize , phase 2 study IDO inhibitor , INCB024360 versus tamoxifen biochemical recurrent ovarian cancer patient follow complete remission first-line chemotherapy .</brief_summary>
	<brief_title>A Phase 2 Study IDO Inhibitor INCB024360 Versus Tamoxifen Subjects With Biochemical-recurrent-only EOC , PPC FTC Following Complete Remission With First-line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Subjects receive firstline chemotherapy , must platinumcontaining regimen . Subjects receive maintenance paclitaxel , bevacizumab , alternative maintenance therapy ( e.g . vaccine ) eligible enrollment provide discontinue therapy least 4 week prior taxane , least 8 week bevacizumab , receive medical monitor approval time lapse alternative maintenance therapy prior randomization recover toxicity less Grade 2 . Subject must currently remission clinical radiological criterion ( Response Evaluation Criteria Solid Tumors [ RECIST 1.1 ] ) . . If PET scan highresolution CT scan perform demonstrate new disease &lt; /= 1 cm , subject would eligible . Clinical remission define : asymptomatic negative physical examination . Scans require post completion platinumcontaining therapy document disease remission . Prior firstline regimen , CA 125 must elevate first diagnosis , must normalize firstline therapy/regimen , currently elevate : a. CA 125 elevation define 2 consecutive measurement Upper Limit Normal ( ULN ) least 42 week apart , second measure show increase first measurement 1 . If CA 125 ≥ 2 × ULN confirmatory value need 1 week apart . 2 . CA 125 elevation define value least 2 × ULN 2 occasion least 1 week apart ( UK ONLY REQUIREMENT ) . CA 125 elevation must least 3 month completion firstline platinumcontaining regimen . Documentation least 1 normal CA 125 level approximately 3 month follow first line therapy require . Subjects must available archived tumor tissue . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate renal , hepatic , bone marrow function base screen laboratory assessment . Subjects evidence new disease ( &gt; 1 cm ) include new ascites confirm image . Any prior antitumor systemic therapy except firstline chemotherapy associate previous CA 125 normalization maintenance paclitaxel , bevacizumab , alternative maintenance therapy approve medical monitor . Subjects prior radiotherapy within 3 month randomization recover radiotherapyrelated toxicity , receive radiation therapy chest within 3 month randomization , history radiation pneumonitis . Subjects protocolspecified active autoimmune process except vitiligo thyroiditis . Subjects receive investigational study drug indication , immunologicalbased treatment reason ( except complete adjuvant therapy medical monitor approval ) , potent CYP3A4 inducer inhibitor . Subjects receive monoamine oxidase inhibitor ( MAOIs ) within 21 day prior screen ; subject ever Serotonin Syndrome ( SS ) receive 1 serotonergic drug . Subjects tamoxifen therapy contraindicate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>FIGO Stage III IV EOC</keyword>
	<keyword>PPC FTC</keyword>
	<keyword>increase CA 125</keyword>
</DOC>